Pre-Seed Startup Valuation Methods Without Revenue
Learn the five investor methods that actually drive pre-seed valuations.
Pre-seed valuation without revenue isn't guesswork dressed up as math. It's a set of specific, repeatable methods that investors run on every deal, whether they say so out loud or not. Founders who know which method is being applied to them walk into the room with leverage. Founders who don't are just hoping the number feels fair.
Here's the thing nobody tells first-time founders: a discounted cash flow model needs cash flow. An EBITDA multiple needs earnings. At pre-seed, most companies have neither. Some don't even have a finished product yet. So investors aren't calculating intrinsic value, they're making a judgment call under uncertainty, and that judgment call follows patterns you can learn.
The number matters more than founders think it does in the moment. Price too high relative to actual traction, and the seed round becomes a down round, which spooks future investors and makes every subsequent raise harder to negotiate. Get the pre-seed number roughly right, and every round after it gets easier to negotiate.
What the current market actually looks like for pre-seed deals
Numbers first, context second. In the US, the median pre-seed pre-money valuation sat at $7.7 million as of the end of Q3 2025, down from $8.0 million the prior quarter, according to the Pitchbook-NVCA Venture Monitor Report. Separate analysis put the 2025 average closer to $5.7 million. Practitioners tend to describe a workable range of $500,000 to $5 million pre-money, aiming for 10% to 20% dilution. For US software companies raising between $500K and $1.5M in 2023 and 2024, deals mostly priced between $3 million and $8 million pre-money, with the median landing around $5 million.
Europe tells a similar story at a different scale. The median pre-seed pre-money valuation in Europe jumped to €3.3 million in 2024, nearly double the €1.7 million recorded in 2023, per data published by Seedblink. UK pre-seed rounds averaged around £3.2 million in 2024 and 2025, up 31% from the year before. Even with that growth, European numbers still run 20% to 30% below US comparables.
Round size matters just as much as valuation, and it's worth sitting with this for a second: 45% of pre-seed rounds in Q3 2025 raised less than $250,000, up from 39% the quarter before. Most deals are small. Only 10% to 15% of pre-seed rounds clear $2.5 million, and average fund sizes at this stage have been shrinking since 2023.
Then there's AI, which has split the market into two tiers. Non-AI startups are pricing at 2019 and 2020 norms, roughly $6 million to $10 million at pre-seed. AI and ML infrastructure startups are pricing at or above 2021 peak levels. Investors including Bill Gurley and Vinod Khosla have said publicly that plenty of AI "wrapper" companies, meaning thin interfaces sitting on top of someone else's foundation model, are priced well beyond what their actual defensibility supports. If you're building in that space, benchmark against your real sector bucket, not the AI headline median. Coming in at $12 million pre-money with no traction, when nothing comparable in your bucket is closing anywhere near that, isn't ambition. It's a math error waiting for an investor to point it out.
The specific methods investors use to arrive at a pre-revenue number
Comparable raises are the starting point for almost every conversation. Investors check what similar deals, same region, same stage, same sector, actually closed at, using Crunchbase, PitchBook (many universities give free access), AngelList, and plain old conversations with founders who raised recently. This isn't a valuation method so much as a market-clearing input: it sets the floor and ceiling before anyone opens a spreadsheet.
From there, a few structured methods do the heavier lifting.
The Scorecard Method, popularized by angel investor Bill Payne, starts from the median comparable valuation and adjusts it up or down based on weighted factors: team strength (30%), market size (a significant portion), product and early traction (15%), competitive environment (10%), sales and marketing channels (10%), and need for additional investment (10%). Say the median comp is $5 million. A strong team with weak early traction might land the company somewhere between $4.5 million and $5.5 million. The value here isn't precision, it's that the reasoning is explicit and defensible in a meeting instead of vibes-based.
The Berkus Method works differently. It assigns up to $500,000 of value across five specific risk-reducing factors, capping total pre-money value at a relatively low ceiling: a sound idea, a working prototype, a quality management team, strategic relationships, and early evidence of sales or market feedback. It was built for pre-revenue companies specifically, and it's a risk-reduction framework, not a growth projection. Because it caps at $2.5 million, it mostly applies to very early concepts. At the higher end of pre-seed, it's usually a cross-check, not the main event.
The Risk Factor Summation Method is the Scorecard's more granular cousin. It starts from a base valuation and walks through roughly a dozen specific risks: regulatory exposure, competitive pressure, manufacturing complexity, IP defensibility, and more. Same logic as Scorecard: identified risk lowers the number, mitigated risk raises it, just sliced finer.
Then there's the VC method, which founders rarely see explained but should understand cold. The investor starts from a plausible exit value, applies a target return multiple (often 10x to 30x at this stage), accounts for dilution across future rounds, and works backward to figure out how much ownership they need today to hit that return. This is exactly why market size claims aren't just a slide, they're an input. A $50 million TAM and a $5 billion TAM produce two completely different exit ceilings, and that ceiling drives the investor's entire return math. Founders who understand this can frame their market argument in terms that actually move the investor's model, not just their enthusiasm.
Last, a practical sanity check: round-size math. Raising $750,000 at a target of 15% dilution implies a $5 million post-money valuation, which implies $4.25 million pre-money. Run this on any proposed number before you walk into the room. If it doesn't hold together, something's off.
The non-financial signals that move a pre-seed number up or down
With no revenue on the table, investors are really valuing three things: team, market, and narrative. Financial projections get discounted to near zero, because everyone in the room knows a first-year revenue forecast from a company with no customers is closer to fiction than forecast.
Team matters first. A repeat founder with a prior exit can justify a meaningfully higher number on reputation alone. Domain expertise, technical depth, and a track record of recruiting good people all count. Underneath the questions about your background, investors are really asking one thing: can this person figure things out fast when the plan falls apart?
Market size isn't decoration, either. It plugs straight into the VC method's exit ceiling. A specific, bottoms-up market sizing argument signals rigor. A slide that says "$50 billion TAM" with no math behind it signals the opposite.
Traction counts for more than people assume, and it doesn't require revenue to exist. A sizeable waitlist, signed letters of intent, pilot customers using an unpaid product, even conversion data from a scrappy landing page test, all of it moves the needle. Quantify whatever you've got. If a $200 ad spend test produced a meaningful signup conversion rate, say that number out loud. It tells the investor you test assumptions before you spend real money, and every scrap of early signal lowers the perceived risk, which is the one lever every valuation method responds to.
Competitive crowding pulls the number down, particularly with no clear point of difference. In deep tech and AI specifically, a genuine technical moat earns real credit. A thin wrapper around someone else's model does not, and increasingly, investors know the difference on sight.
Narrative coherence closes the loop. Investors are quietly checking whether the founder actually understands the problem or is just excited about it. A muddled pitch reads as execution risk, and every method on this list penalizes execution risk somewhere in the math.
One negotiating note worth remembering: give a specific number when asked, not a range. A range invites the investor to anchor lower. Have one or two sentences ready that tie your number to comps and to your specific traction: comparable B2B SaaS rounds in your region are pricing between $4 million and $6 million, and given the team and the signed LOIs, you're pricing at the top of that band. That's a sentence an investor can argue with on the merits, not a feeling they can talk you out of.
How SAFEs work and why the valuation cap is the number that actually matters
SAFEs run the pre-seed market now. Per Carta data, 92% of all pre-priced rounds in Q3 2025 used one. A SAFE (Simple Agreement for Future Equity) is a short contract that converts a cash investment into equity once a priced round happens later. It isn't debt: no interest, no maturity date, nothing to repay if the company stalls. Y Combinator introduced it in late 2013, drafted by then-YC partner Carolynn Levy, as a cleaner alternative to the convertible note.
One structural shift matters more than founders usually realize. YC moved from pre-money to post-money SAFEs in September 2018, and post-money is now the standard, with 85% market adoption. Under a post-money SAFE, each new SAFE only dilutes the founders, not the earlier SAFE holders. That means founders need to track every SAFE they've issued closely, because the dilution stacks on the founder side alone.
On deal terms, Carta's data shows 61% of SAFEs use a valuation cap only, 30% include both a cap and a discount, 8% use a discount only, and 1% use neither. YC actually dropped the cap-plus-discount combo back in 2021, saying it never found a situation where that combination made sense for either side. And yet 30% of SAFEs still carry both, negotiated custom, which usually just means more dilution than the founder needed to give up.
Cap sizes as of Q2 2025 (Carta): rounds under $250,000 carried a median valuation cap of $7.5 million; rounds between $250,000 and $500,000 carried a median of $10 million; pre-money convertible notes under $250,000 carried a median cap of $7 million. Broadly, pre-seed SAFEs in 2024 and 2025 land somewhere between $4 million and $15 million, with seed-stage SAFEs running higher, often $10 million to $30 million. Sector-level cap differences are real, and founders in specialized fields like biotech should benchmark against their own sector rather than the broader pre-seed median.
Here's the trap: SAFEs were built to be fair to both sides, but founders who stack multiple SAFE rounds, especially at low caps, often get hit with more dilution at conversion than they expected. Through 2025, valuation caps shifted across deal sizes through the year, with convertible note caps generally sitting lower than SAFE caps at comparable round sizes, based on available Carta data. Deal volume tells its own story too: Q4 2025 saw only 11,672 SAFEs and convertible notes issued, the lowest count in recent years, yet that group still represented $2.62 billion in total investment, roughly in line with prior quarters. Fewer deals, same money. Read into that what you will.
How to calculate dilution and stress-test a valuation before the meeting
Three calculations, and every founder should be able to run them without opening a spreadsheet.
Post-money valuation equals pre-money valuation plus the investment amount. Straightforward addition, but it's the number every other calculation depends on.
Investor ownership equals the investment amount divided by the post-money valuation. Raise $750,000 at a $5 million post-money, and the investor owns 15%. Run this for every SAFE on the table, not just the current one, because they stack.
Price per share equals pre-money valuation divided by total shares outstanding. This locks in the conversion math for whenever the priced round actually happens, which is the moment SAFE holders find out exactly what their paper turned into.
Run all three before the meeting, not during it. A founder who can answer "what does this do to my ownership at seed" without reaching for a calculator is a founder an investor takes seriously, and that, more than any pitch deck slide, is what actually moves a pre-seed number.
